How Pharmaceutical Companies Are Using Quantum Computing in 2026

Picture a computational chemist sitting at a workstation on a pharmaceutical R&D floor in Cambridge, Massachusetts, on a Tuesday morning in early 2026. On her screen, a molecular docking simulation is running, not on a rack of GPU servers in a data center down the hall, but on a 127-qubit IBM quantum processor accessed over the cloud. The molecule she is modeling is a potential kinase inhibitor, one of hundreds of candidates that her team has already screened using classical supercomputers over the past eighteen months. What the quantum simulation is doing differently is modeling the molecule's electron correlation effects with a fidelity that classical methods can only approximate. The results will not be perfect, not yet, but they will be meaningfully better than what her team could produce a year ago, and the gap is narrowing fast.

This is not a speculative scenario pulled from a technology white paper. It is a composite picture of real work happening at real companies right now. From Pfizer's computational chemistry teams to Bayer's clinical trial optimization units to Novo Nordisk's protein modeling groups, the pharmaceutical industry has moved decisively from curiosity to commitment on quantum computing. The investment is real, the partnerships are signed, and the early results, while modest by the standards of what fault-tolerant quantum hardware will eventually deliver, are already influencing how drugs get made.

To understand why this is happening now, before quantum computers have achieved the error-corrected, fault-tolerant performance that theorists say is needed for truly transformative results, you need to understand the economics of pharmaceutical research and the particular structure of the problems that quantum computing is best positioned to solve. The industry spends, by some estimates, between two and three billion dollars to bring a single new drug to market, and it does so over timelines that span a decade or more. Even marginal improvements in computational efficiency at the early discovery stage can translate into enormous downstream savings. In that context, the willingness of major pharma companies to invest in quantum computing today, despite its limitations, makes a great deal of rational sense.

The Pharmaceutical Industry's Quantum Bet

The pharmaceutical industry's engagement with quantum computing has accelerated rapidly since 2023, when the combination of improved qubit counts, better error mitigation techniques, and more sophisticated quantum chemistry algorithms began to make near-term applications look credible rather than theoretical. By 2025, virtually every major pharmaceutical company had either signed a formal quantum computing partnership, established an internal quantum research team, or both. The companies leading this wave include Pfizer, Bayer, Roche, AstraZeneca, Merck, Novo Nordisk, Boehringer Ingelheim, and Johnson & Johnson, each approaching the technology from slightly different angles but sharing a common conviction that quantum advantage in drug discovery is no longer a question of whether but when.

The specific problems these companies are targeting fall into a handful of well-defined categories. Molecular simulation is the most discussed: quantum computers, by operating natively in the quantum mechanical framework that governs molecular behavior, can in principle model electron correlation effects more accurately than classical computers, which must resort to increasingly expensive approximations as molecular complexity grows. Drug-target binding prediction, protein folding energetics, and the identification of off-target interactions are all problems where better simulation could reduce costly late-stage failures. Beyond simulation, companies are also exploring quantum approaches to combinatorial optimization problems in clinical trial design, supply chain logistics, and genomic data analysis.

What makes the current moment particularly interesting is that the companies moving fastest are not simply waiting for a future generation of hardware to arrive. They are doing real computational work with today's noisy intermediate-scale quantum, or NISQ, devices, using hybrid classical-quantum algorithms that offload specific subproblems to quantum processors while handling the broader computational workload classically. If you want to understand the theoretical basis for why this hybrid approach is promising, the core concepts are explained well in our overview of how quantum computing is reshaping drug discovery. But the companies themselves are less interested in theoretical frameworks than in measurable results, and those results are starting to emerge.

IBM and Cleveland Clinic: A Model Partnership

One of the most closely watched quantum partnerships in life sciences is the agreement between IBM and the Cleveland Clinic, announced in 2021 and now well into its operational phase. The partnership centers on the Discovery Accelerator, a joint research initiative that has given Cleveland Clinic direct on-site access to IBM quantum hardware, making it one of the first healthcare institutions in the world to have a dedicated quantum computer installed within a medical research facility. The research agenda is broad, covering genomics, drug discovery, and population health analytics, but the molecular simulation work is perhaps the most consequential from a pharmaceutical standpoint.

Researchers at Cleveland Clinic have been using IBM's quantum processors to explore problems in computational chemistry relevant to cancer and cardiovascular disease. The team, which includes quantum computing scientists working alongside oncologists and cardiologists, has published work on quantum approaches to simulating small molecules relevant to drug design. The results have been honest about current limitations: today's quantum hardware cannot yet outperform the best classical supercomputers on the specific molecular sizes that are most relevant to drug discovery. But the trajectory is the point. The Cleveland Clinic team has been explicit about building expertise and workflows now so that when fault-tolerant hardware arrives, the scientific community has the methods and trained researchers ready to use it.

IBM's pharmaceutical partnerships extend well beyond Cleveland Clinic. The company has established quantum network relationships with multiple major drug companies, providing access to its quantum systems and the Qiskit software ecosystem. For IBM, pharmaceutical clients represent one of the most commercially important use cases for quantum computing, both because of the size of the industry and because the specific problems pharma companies face, molecular simulation in particular, align well with the theoretical strengths of quantum hardware. The relationship is symbiotic: pharma companies get early access to emerging technology and influence over the research roadmap, while IBM gains industry-specific validation and the kind of domain expertise that accelerates hardware improvements.

Pfizer and Molecular Docking

Pfizer has been among the most publicly engaged major pharmaceutical companies in quantum computing, and its focus has centered on one of the most computationally demanding problems in drug discovery: molecular docking. Docking is the process of predicting how a candidate drug molecule will bind to a target protein, specifically which orientation and position it will adopt within the protein's active site and how tightly it will bind. The accuracy of docking predictions has an enormous practical impact: a better docking score correlates, imperfectly but meaningfully, with better binding affinity in laboratory assays, and better binding affinity in the laboratory correlates with better efficacy in animals and eventually in humans.

Classical docking algorithms, including the widely used AutoDock and Glide platforms, work by exploring a vast conformational space using heuristic search methods. They are fast enough to screen millions of compounds but sacrifice physical accuracy for speed, relying on simplified force fields and sampling strategies that can miss important binding modes or overestimate binding affinity for certain classes of molecules. Quantum approaches, specifically variational quantum eigensolvers applied to the electronic structure of the ligand-receptor complex, offer a path to better accuracy by treating the quantum mechanical character of the binding interaction more faithfully.

Pfizer's quantum chemistry team has published work exploring these approaches, and the company has maintained active collaborations with quantum hardware and software companies. The honest assessment from Pfizer researchers has been that current quantum hardware is not yet capable of delivering better docking predictions than the best classical methods for realistic drug-sized molecules. The active sites of pharmaceutically relevant proteins involve dozens of atoms whose electronic structure must be modeled accurately, and the qubit requirements for that level of simulation exceed what current hardware can reliably support. But the research investment is about closing that gap, and Pfizer has been explicit about viewing quantum docking as a near-term priority as hardware scales.

It is worth putting Pfizer's quantum work in the context of the company's broader computational strategy. Pfizer has been a leader in applying artificial intelligence and machine learning to drug discovery, and its quantum computing efforts are integrated into that broader program rather than existing as a separate initiative. The company is exploring quantum machine learning algorithms that could, in principle, find patterns in molecular data that classical neural networks miss. This intersection of quantum computing and machine learning is one of the most contested areas in the field, with significant disagreement among researchers about whether near-term quantum hardware can provide meaningful advantages over classical ML. Pfizer's position appears to be one of disciplined experimentation: test the hypotheses rigorously and follow the data.

Bayer and Trial Efficiency

Bayer has taken a somewhat different approach to quantum computing than its peers in the pharmaceutical space, focusing significant attention on the optimization problems in clinical trial design rather than molecular simulation alone. Clinical trials are extraordinarily expensive operations, and the design of a trial, specifically the selection of patient subgroups, dosing schedules, endpoint definitions, and sample sizes, has an enormous impact on both cost and the probability of success. Combinatorial optimization, the kind of problem that involves finding the best solution from an astronomically large number of possible configurations, is one area where quantum computers have a credible theoretical advantage over classical approaches.

Bayer has been working with quantum computing partners to explore whether quantum optimization algorithms, particularly variants of the quantum approximate optimization algorithm, or QAOA, can identify better trial designs than classical optimization methods. The company has discussed research suggesting that quantum-optimized trial designs could reduce the required patient sample sizes meaningfully for certain trial types, with some internal estimates pointing to reductions in the range of 30 percent under specific conditions. It is important to be precise about what that figure means: it comes from Bayer's own research program under specific modeling assumptions and for specific types of trials, and it should not be generalized carelessly to all clinical research. But the direction of the result is credible, because the underlying mathematics of quantum optimization is well-understood, and trial design is a problem structure that fits the quantum approach reasonably well.

The potential impact of even a modest reduction in clinical trial sample sizes would be substantial. Trials in Phase III, the final stage of human testing before regulatory approval, routinely enroll thousands of patients over multiple years at a cost that can run into hundreds of millions of dollars. Reducing the required enrollment by even a fraction of that would accelerate timelines and reduce costs in ways that ripple through to the speed at which effective medicines reach patients. Bayer's quantum optimization work is therefore not an academic exercise but a commercially motivated research program with a clear line from technical results to business outcomes.

The European Pharma Push: Roche, AstraZeneca, and Novo Nordisk

European pharmaceutical companies have been among the most aggressive adopters of quantum computing partnerships, driven in part by a European policy environment that has prioritized quantum technology investment and in part by the competitive pressure of operating in a global industry where computational advantages translate directly into pipeline value. Roche, AstraZeneca, and Novo Nordisk represent three distinct approaches to quantum engagement, and each offers a window into the range of ways a major pharmaceutical company can position itself in this emerging technology landscape.

Roche has built its quantum strategy around partnerships with both hardware companies and specialized quantum software firms. The company's computational biology and medicinal chemistry teams have been exploring quantum algorithms for electronic structure calculations relevant to oncology drug targets, which tend to involve complex transition metal chemistry that is particularly challenging for classical methods. Roche has also been involved in quantum computing consortia in Europe, collaborating with academic research groups and national laboratories to develop domain-specific quantum software tools for pharmaceutical applications. The company has been measured in its public claims, consistently describing its quantum program as a long-term investment with uncertain near-term returns but high strategic importance.

AstraZeneca has pursued a complementary approach, partnering with multiple quantum computing platforms and focusing on the intersection of quantum computing and quantum chemistry for respiratory and cardiovascular drug targets. The company has been particularly active in exploring quantum approaches to protein-ligand binding free energy calculations, which are among the most computationally demanding tasks in structure-based drug design. If you want to understand how quantum simulation compares to classical approaches for these kinds of problems, our piece on quantum simulation versus classical methods in pharma covers the technical landscape in detail. AstraZeneca's researchers have published work showing that hybrid quantum-classical methods can, for small model systems, produce results that agree well with high-level classical methods at lower computational cost. Scaling those results to drug-relevant molecular sizes remains the central challenge.

Novo Nordisk, best known for its dominance in diabetes and obesity treatment, has brought quantum computing to bear on one of the most relevant computational challenges in its pipeline: the behavior of large biomolecules, particularly the protein-drug interactions central to its GLP-1 receptor agonist programs. The company has established a quantum computing research group focused on applying variational quantum algorithms to model the conformational dynamics of peptide-based drugs as they interact with their target receptors. Peptides are notoriously difficult to model classically because their biological activity depends on subtle conformational changes that require accurate treatment of quantum mechanical effects. Novo Nordisk's bet is that quantum computing will eventually provide a systematic advantage in this specific domain, and it is investing in the technical capability to capitalize on that advantage when hardware matures. To understand the broader context of what quantum computing means for medicine as a whole, our explainer on what quantum medicine actually means provides useful background on the field's scope and ambitions.

Merck and Quantum Machine Learning

Merck has carved out a distinctive position in the pharmaceutical quantum computing landscape by focusing substantially on quantum machine learning, rather than pure quantum simulation. The company's computational scientists have been investigating whether quantum neural networks and quantum kernel methods can extract structure-activity relationships from molecular data that classical machine learning algorithms struggle to capture. The theoretical basis for this hope is the idea that quantum circuits can efficiently represent certain high-dimensional feature spaces that are exponentially expensive to represent classically, potentially giving quantum ML models an edge on problems where the underlying data has a quantum mechanical structure.

In practice, the results from quantum machine learning in chemistry have been mixed, and Merck's researchers have been honest about that complexity. The field has seen a wave of skeptical theoretical analysis suggesting that many proposed quantum ML advantages over classical methods may be illusory in practice, because classical neural networks can often efficiently approximate the same function spaces that quantum circuits are claimed to have exclusive access to. The genuine cases where quantum ML outperforms classical ML on real pharmaceutical data remain limited, and the community is actively working to identify the problem structures where the advantage is real and robust. Merck's approach appears to be one of genuine scientific engagement with that open question, running controlled comparisons and publishing results rather than committing to a predetermined conclusion.

Beyond machine learning, Merck has also been active in quantum computing research related to its vaccine and biologics programs, exploring quantum algorithms for analyzing the complex immune response dynamics that determine vaccine efficacy. This is a harder problem than small-molecule drug design in some ways, because the relevant biomolecular systems are larger and the connection between quantum mechanical effects and macroscopic immune outcomes is more indirect. But Merck has the scale and the scientific depth to invest in long-horizon research, and quantum computing for biologics represents a genuinely novel scientific frontier.

Why Invest Now, Before Fault Tolerance?

A reasonable question to ask about all of this activity is: why now? Quantum computing researchers are fairly unified in the view that truly transformative pharmaceutical applications, accurate simulation of drug-sized molecules with hundreds of atoms in biologically realistic environments, will require fault-tolerant quantum computers with millions of physical qubits, systems that do not yet exist and may not exist for another decade or more. Given that timeline, why are companies spending serious money on partnerships, internal teams, and computational experiments today?

The answer is multifaceted, and it reflects a sophisticated understanding of how transformative technologies develop and how competitive advantages are built. The first and most straightforward reason is workforce development. Quantum computing is a genuinely difficult discipline that requires training in quantum mechanics, algorithm design, error mitigation, and domain-specific applications. The pool of people who can do this work well is small and growing slowly. Companies that hire and train quantum computing scientists now will have a material advantage over competitors who wait until the technology is more mature, because by then the talent will be even scarcer and more expensive. Building a quantum computing team is a multiyear process, and the time to start is before you urgently need one.

The second reason is algorithmic readiness. The history of computing is full of cases where algorithmic innovation was the primary driver of performance improvements, rather than raw hardware advances. Quantum computing is no different. The hybrid quantum-classical algorithms that pharmaceutical companies are developing and refining today will become dramatically more powerful as qubit counts increase and error rates fall. A company that has been running these algorithms on today's hardware understands their practical behavior, their failure modes, and their scalability properties in a way that cannot be learned from theoretical analysis alone. When better hardware arrives, the companies with operational experience will be able to scale their methods immediately, while those starting from scratch will face a steep learning curve.

The third reason is that some value is being extracted even today. It is easy to overstate this: current quantum hardware is not delivering the kinds of improvements in drug discovery productivity that will eventually be possible. But quantum computing is already contributing to scientific understanding in specific narrow contexts, particularly in the simulation of small model systems that illuminate the behavior of larger drug-relevant molecules, and in optimization problems where the problem structure is well-matched to available algorithms. These contributions are incremental, but in an industry where incremental improvements compound over long development timelines, they are not trivial.

There is also a competitive dynamic at work. No major pharmaceutical company wants to be the one that dismissed quantum computing as premature and then found itself technologically behind when the technology matured. The potential downside of underinvesting is severe: if quantum computing delivers even a fraction of its theoretical promise for drug discovery, the companies with quantum capabilities built into their research infrastructure will be able to identify better drug candidates faster, optimize trials more efficiently, and bring products to market ahead of competitors who lack those capabilities. The expected value calculation favors investment even under significant uncertainty about the timing and magnitude of quantum advantage.

What the Pipeline Looks Like

Looking across the pharmaceutical industry's quantum computing investments as of mid-2026, a reasonably clear picture of the near-term pipeline emerges. The first applications to deliver commercially relevant results will almost certainly be in molecular simulation for small molecules, specifically the calculation of binding free energies and electronic structure properties for drug candidates against well-characterized targets. This is the area where the theoretical justification for quantum advantage is strongest and where the hardware requirements, while still challenging, are closest to what current and near-future quantum processors can support.

Clinical trial optimization represents a second near-term application category. The combinatorial optimization problems in trial design are well-structured for quantum approaches, and the hardware requirements are somewhat less demanding than for molecular simulation. Bayer's work in this area is the most visible example, but other companies are pursuing similar research. Researchers estimate that quantum-optimized trial designs could become a standard tool in the pharmaceutical statistician's toolkit within the next three to five years, as quantum hardware continues to improve and the algorithms are validated against real trial data.

Beyond these near-term applications, the longer-term pipeline includes quantum simulation of biological macromolecules relevant to biologics and gene therapy, quantum approaches to analyzing genomic and proteomic datasets of a scale and complexity that strains classical computing resources, and potentially quantum-enhanced materials science for drug delivery systems and formulation chemistry. These applications are further out on the timeline, but the groundwork being laid today by companies like Novo Nordisk, Roche, and AstraZeneca is directly relevant to them.

It is also worth noting the role of the broader quantum computing ecosystem in shaping pharmaceutical applications. The rapid development of quantum software platforms, cloud-based quantum computing services, and specialized quantum chemistry software tools has significantly lowered the barrier to entry for pharmaceutical researchers without deep quantum computing expertise. Platforms from IBM, IonQ, Quantinuum, and PsiQuantum have each made investments in pharmaceutical-specific tooling, and a growing number of startups are building quantum software solutions specifically for drug discovery. This ecosystem development accelerates pharmaceutical adoption by reducing the need for every company to build foundational quantum computing expertise from scratch.

The trajectory of pharmaceutical quantum computing in 2026 is one of accelerating commitment and gradually maturing results. The companies that are furthest along are those that combined early and serious investment with intellectual honesty about what current hardware can and cannot deliver. They are not claiming victories that the technology has not yet earned. They are building the infrastructure, the expertise, and the algorithmic repertoire that will be essential when fault-tolerant quantum hardware arrives. By the time that hardware exists, the leading pharmaceutical companies will not be learning quantum computing; they will already be running it at scale. That is the strategic logic of the quantum bet in pharma today, and by the evidence of the investments being made across the industry, it is a logic that the world's leading drug companies find compelling.